Boston Partners Amgen Inc Transaction History

Boston Partners

$80.6 Billion
Q3 2024

A detailed history of Boston Partners transactions in Amgen Inc stock. As of the latest transaction made, Boston Partners holds 2,292,180 shares of AMGN stock, worth $637 Million. This represents 0.92% of its overall portfolio holdings.

Number of Shares

2,292,180

Previous 2,294,410 0.1%

Holding current value

$637 Million

Previous $717 Million 3.02%

% of portfolio

0.92%

Previous 0.93%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$309.38 - $337.38 $689,917 - $752,357	-2,230 Reduced 0.1%	2,292,180 $739 Million
Q2 2024 Aug 13, 2024	BUY	$262.75 - $319.31 $15 Million - $18.2 Million	57,076 Added 2.55%	2,294,410 $717 Million
Q1 2024 May 13, 2024	BUY	$268.87 - $324.56 $129 Million - $156 Million	481,214 Added 27.4%	2,237,334 $636 Million
Q4 2023 Feb 07, 2024	SELL	$255.7 - $288.46 $57.4 Million - $64.8 Million	-224,579 Reduced 11.34%	1,756,120 $506 Million
Q3 2023 Nov 07, 2023	SELL	$218.65 - $271.46 $5.78 Million - $7.17 Million	-26,420 Reduced 1.32%	1,980,699 $532 Million
Q2 2023 Aug 10, 2023	BUY	$214.27 - $253.37 $38.2 Million - $45.1 Million	178,152 Added 9.74%	2,007,119 $446 Million
Q1 2023 May 09, 2023	BUY	$225.79 - $275.2 $196 Million - $239 Million	868,298 Added 90.38%	1,828,967 $442 Million
Q4 2022 Feb 07, 2023	SELL	$229.03 - $291.01 $43.7 Million - $55.5 Million	-190,671 Reduced 16.56%	960,669 $252 Million
Q3 2022 Nov 09, 2022	SELL	$224.46 - $253.15 $6.72 Million - $7.57 Million	-29,919 Reduced 2.53%	1,151,340 $260 Million
Q2 2022 Aug 10, 2022	BUY	$230.71 - $256.74 $6.2 Million - $6.9 Million	26,858 Added 2.33%	1,181,259 $287 Million
Q1 2022 May 10, 2022	BUY	$219.27 - $242.57 $4.25 Million - $4.7 Million	19,366 Added 1.71%	1,154,401 $279 Million
Q4 2021 Feb 04, 2022	BUY	$198.88 - $227.6 $82 Million - $93.8 Million	412,337 Added 57.06%	1,135,035 $255 Million
Q3 2021 Nov 05, 2021	BUY	$212.27 - $248.7 $6.32 Million - $7.4 Million	29,760 Added 4.29%	722,698 $154 Million
Q2 2021 Aug 12, 2021	SELL	$233.58 - $259.14 $111 Million - $123 Million	-475,983 Reduced 40.72%	692,938 $169 Million
Q1 2021 May 10, 2021	BUY	$221.91 - $258.6 $43.6 Million - $50.8 Million	196,342 Added 20.19%	1,168,921 $291 Million
Q4 2020 Feb 04, 2021	BUY	$216.38 - $257.67 $206 Million - $245 Million	952,081 Added 4644.75%	972,579 $224 Million
Q3 2020 Nov 13, 2020	SELL	$234.65 - $260.95 $284,630 - $316,532	-1,213 Reduced 5.59%	20,498 $5.21 Million
Q2 2020 Aug 12, 2020	BUY	$197.81 - $242.74 $1.51 Million - $1.85 Million	7,640 Added 54.3%	21,711 $5.12 Million
Q1 2020 May 13, 2020	BUY	$182.24 - $241.7 $321,471 - $426,358	1,764 Added 14.33%	14,071 $2.85 Million
Q4 2019 Feb 06, 2020	BUY	$189.21 - $243.2 $2.33 Million - $2.99 Million	12,307 New	12,307 $2.97 Million
Q4 2019 Feb 05, 2020	SELL	$189.21 - $243.2 $1.52 Million - $1.96 Million	-8,057 Closed	0 $0
Q3 2019 Nov 20, 2019	SELL	$174.11 - $208.62 $483,851 - $579,754	-2,779 Reduced 25.65%	8,057 $1.56 Million
Q2 2019 Aug 09, 2019	BUY	$166.7 - $195.41 $58,011 - $68,002	348 Added 3.32%	10,836 $2 Million
Q4 2018 Feb 07, 2019	SELL	$178.4 - $208.25 $8,741 - $10,204	-49 Reduced 0.47%	10,488 $2.04 Million
Q3 2018 Nov 14, 2018	BUY	$185.29 - $208.89 $67,074 - $75,618	362 Added 3.56%	10,537 $2.18 Million
Q2 2018 Aug 03, 2018	BUY	$166.05 - $186.51 $37,029 - $41,591	223 Added 2.24%	10,175 $1.88 Million
Q1 2018 May 04, 2018	BUY	$169.43 - $198.0 $118,262 - $138,204	698 Added 7.54%	9,952 $1.7 Million
Q4 2017 Feb 01, 2018	SELL	$168.79 - $188.59 $108,531 - $121,263	-643 Reduced 6.5%	9,254 $1.61 Million
Q3 2017 Nov 02, 2017	BUY	$167.29 - $191.0 $1.66 Million - $1.89 Million	9,897	9,897 $1.85 Million

Others Institutions Holding AMGN

# of Institutions

3,123

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $149B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Boston Partners, based on Form 13F filings with the SEC.

News

Stay updated on Boston Partners with notifications on news.

Account